Results 101 to 110 of about 145 (143)

Cardiovascular Pharmacology of the Vasodilator-Cardiotonic Agent, 349U85

Journal of Cardiovascular Pharmacology, 1992
349U85 is a chemically novel, nonglycoside, noncatecholamine cardiotonic-vasodilator agent with a unique cardiovascular profile in vitro and in vivo. 349U85 and milrinone, 10(-6) to 3 x 10(-5) M each, produce concentration-dependent increases in tension development of 33-60% and 37-60%, respectively, with corresponding 5-18% and 17-55% increases in ...
R P, Steffen, W B, Wastila
openaire   +2 more sources

Vasodilating Agents in Augmentation of Skin Flap Survival

Otolaryngology–Head and Neck Surgery, 1979
Skin flap necrosis is a serious problem in reconstructive head and neck surgery. Currently, the only clinically effective means of preventing flap necrosis is delay. Hypothesized mechanisms of delayed and experimental methods of increasing flap survival are discussed.
J M, Toomey, J M, Conoyer, J H, Ogura
openaire   +2 more sources

Pharmacokinetics of Vasodilating Agents

1986
Studies on the metabolism of nitroglycerin in various animal species have shown distinct differences making it problematic to extrapolate from experimental animal data to humans. Needleman et al. (1972) found complete inactivation of nitrates following oral administration in rats as a result of the first-pass effect in the liver.
openaire   +1 more source

The effectiveness of local injections of vasodilating agents to produce vasodilation in subcutaneous tissue in rabbits

Clinical Physiology, 1985
Summary. . The isotope washout method has been widely used to study characteristics of the microcirculation in localized vascular beds. Some of these studies have used local injections of vasodilating agents to maximally dilate the vascular bed. This study was undertaken to determine the agent most effective in producing this critical vasodilation.A ...
H J, Duncan, I B, Faris, N J, DeYoung
openaire   +2 more sources

Mechanism of Action of Vasodilating Agents

1988
The development of heart failure is accompanied by the activation of neuroendocrine compensatory mechanisms (see chapter “Endocrine response to heart failure”). Although these responses are initially aimed at preserving cardiovascular homeostasis, they eventually lead to a further deterioration of myocardial performance due to excessive ...
J. Biollaz, A. Munafo, T. Buclin
openaire   +1 more source

Effects of Vasodilator Antihypertensive Agents on Renal Function

Journal of Cardiovascular Pharmacology, 1987
The effects of calcium antagonist and noncalcium antagonist vasodilator antihypertensive agents were examined using renal clearance, hemodynamic, and micropuncture techniques in anesthetized normotensive dogs, rats, and conscious spontaneously hypertensive rats.
openaire   +2 more sources

An in Vitro Technique for Testing Nasal Vasodilating Agents

Otolaryngology–Head and Neck Surgery, 1980
An in vitro method for testing vasoactive drugs on nasal blood vessels is described. Isolated dog nasal mucosa contracts when treated with nasal decongestant or stimulated electrically. Vasodilating drugs inhibit this contraction. Atropine blocks the effects of acetylcholine on this tissue.
openaire   +2 more sources

The Treatment of Shock with Vasodilating Agents

1985
It is a great honour for me to have been asked to describe the medical field in which I worked in the early 1950s, which led to a medical change in the approach to the treatment of shock. In those years change in more than one respect took place in the treatment of severely ill patients.
openaire   +1 more source

Chapter 8. Vasodilator and Vasoconstrictor Agents

1969
Publisher Summary This chapter presents an overview of vasodilator and vasoconstrictor agents. Many drugs with diverse pharmacological actions ultimately alter vascular tone. Antihypertensive agents as well as drugs used to treat peripheral vascular diseases are among those that reduce vascular tone.
F.P. Hauck, C.N. Gillis
openaire   +1 more source

[Vasodilator agents and the vascular endothelium].

Annales de cardiologie et d'angeiologie, 1990
The recent discovery of endothelium-derived relaxation factor (EDRF) has altered the traditional classification of vasodilators used in angina pectoris and heart failure. If a vasodilator induces release of EDRF from the epithelium it is classified as endothelium-dependent, if not it is independent.
openaire   +1 more source